Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrocell Science (FCSC)

Fibrocell Science (FCSC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,275
  • Shares Outstanding, K 9,758
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,280 K
  • 60-Month Beta 1.67
  • Price/Sales 1.28
  • Price/Cash Flow N/A
  • Price/Book 2.73
  • Price/Earnings ttm 16.67
  • Earnings Per Share ttm 0.18
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/19/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -164.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.97 +1.01%
on 11/25/19
3.01 -0.33%
on 12/09/19
+0.01 (+0.33%)
since 11/12/19
3-Month
2.91 +3.09%
on 09/18/19
3.01 -0.33%
on 12/09/19
+1.17 (+63.93%)
since 09/12/19
52-Week
1.45 +106.90%
on 12/31/18
3.28 -8.54%
on 03/20/19
+0.98 (+48.51%)
since 12/12/18

Most Recent Stories

More News
Intrexon Reports Third Quarter 2019 Financial Results

Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results...

PTCT : 48.90 (-2.06%)
FCSC : 3.00 (unch)
AQB : 2.79 (+0.72%)
XON : 4.65 (-4.12%)
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - FCSC, PRTO, ARTX, ROAN

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

FCSC : 3.00 (unch)
PRTO : 0.84 (+28.45%)
ARTX : 2.99 (unch)
ROAN : 1.52 (unch)
Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - ROAN, UCFC, SRCI, FCSC

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

ROAN : 1.52 (unch)
UCFC : 10.93 (-2.67%)
SRCI : 4.00 (-2.20%)
FCSC : 3.00 (unch)
Reata Successfully Completes Neuromuscular Disorder Study

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

ABBV : 92.33 (+1.58%)
FCSC : 3.00 (unch)
RETA : 129.50 (-4.37%)
BGNE : 169.08 (+0.02%)
Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of SRC Energy, Pivotal Software, MAM Software Group, and Fibrocell Science on behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of SRC Energy Inc. (NYSE: SRCI), Pivotal Software, Inc. (NYSE: PVTL), MAM Software...

SRCI : 4.00 (-2.20%)
PVTL : 15.00 (-0.13%)
MAMS : 12.12 (+0.17%)
FCSC : 3.00 (unch)
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - PRTO, FCSC, SEMG, UCFC

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

PRTO : 0.84 (+28.45%)
FCSC : 3.00 (unch)
SEMG : 15.02 (-0.27%)
UCFC : 10.93 (-2.67%)
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - UCFC, SEMG, ALDR, FCSC

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

UCFC : 10.93 (-2.67%)
SEMG : 15.02 (-0.27%)
ALDR : 18.88 (-0.21%)
FCSC : 3.00 (unch)
Due to Rising Prevalence of Cancer in U.S., Cancer Therapy Market Showing Rapid Growth

The global cancer therapy market looks like it will continue trend to continue its growth, worldwide. Cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific...

MBRX : 1.0600 (-0.93%)
FCSC : 3.00 (unch)
NTEC : 0.4401 (+12.85%)
MNK : 2.83 (+2.17%)
IMMU : 30.65 (-2.67%)
Fibrocell Up on FDA Designation for Gene Therapy Candidate

Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

FCSC : 3.00 (unch)
ANIK : 34.05 (+2.75%)
XON : 4.65 (-4.12%)
AXGT : 3.19 (+0.95%)
Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?

Is (FCSC) Outperforming Other Medical Stocks This Year?

FCSC : 3.00 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade FCSC with:

Business Summary

Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous...

See More

Key Turning Points

2nd Resistance Point 3.01
1st Resistance Point 3.01
Last Price 3.00
1st Support Level 2.99
2nd Support Level 2.98

See More

52-Week High 3.28
Last Price 3.00
Fibonacci 61.8% 2.58
Fibonacci 50% 2.37
Fibonacci 38.2% 2.15
52-Week Low 1.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar